Biotech | November 15, 2025
Merck to acquire Cidara Therapeutics for $9.2 billion
Diversifying its portfolio to include late-phase antiviral agent
Diversifying its portfolio to include late-phase antiviral agent
The observations are procedural in nature and will be responded to within the stipulated time
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Glenmark will begin distribution in November 2025
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Subscribe To Our Newsletter & Stay Updated
